Amunix Pharmaceuticals, Inc

Dh Technologies Development Pte. Ltd.

Eric Johansen

Volker Schellenberger

Darragh Maccann

Lucas Liu

Andre Frenzel

Viktoriya Dubrovskaya

Bryan Irving

Philipp Kuhn

Milton To

Angela Henkensiefken

James Mcclory

Mika Derynck

The disclosure describes antigen-binding molecules with binding specificity to cluster of differentiationT cell receptor (CD), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.

Compositions targeting prostate-specific membrane antigen and methods for making and using the same

Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.

HER-2 targeted bispecific compositions and methods for making and using the same

Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions. The sequential windowed acquisition is performed without any information about contaminating proteins before data acquisition, and produces data for every product ion of every transmitted precursor ion for the mass range. One or more measured product ion spectra are received, and compared to a library of host cell proteins. One or more host cell contaminants are detected by reporting host cell proteins from the library that match the one or more measured product ion spectra.

SWATH# data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products

Growing community of inventors

Oakland, CA, United States of America

Eric Johansen